Fig. 2.

Adjusted mean change from baseline in the Clinical Disease Activity Index (CDAI) (a, b) and Simplified Disease Activity Index (SDAI) (c, d) at 1 and 2 years, by patient type (Cohort 1: a, c; Cohort 2: b, d). All randomized and treated patients were included in the analysis; n is the number of patients with both post-baseline and baseline measurements. Asterisk indicates patients with seropositive, erosive early RA treated with abatacept versus adalimumab, respectively. The adjusted mean change from baseline at day 365 was − 25.68 (95% CI − 29.88 to − 21.49) versus − 19.28 (95% CI − 23.55 to − 15.02) for CDAI and − 26.71 (95% CI − 31.09 to − 22.33) versus − 20.22 (95% CI − 24.70 to − 15.74) for SDAI. For calculation of the 95% CI within each group, normal approximation was used if n ≥ 5, otherwise the exact method was used. The dagger indicates that adjustment was based on an analysis of covariance model with treatment as a factor and baseline values and DAS28 (CRP) stratification as covariates